Abnormal protein folding and self-assembly causes over 30 cureless human diseases for which no diseasemodifying therapies are available. The common side to all these diseases is formation of aberrant toxic protein oligomers and amyloid fibrils. Both types of assemblies are drug targets, yet each presents major challenges to drug design, discovery, and development. In this review, we focus on two small molecules that inhibit formation of toxic amyloid protein assemblies -the green-tea derivative (-)-epigallocatechin-3-gallate (EGCG), which was identified through a combination of epidemiologic data and a compound library screen, and the molecular tweezer CLR01, whose inhibitory activity was discovered in our group based on rational reasoning, and subsequently confirmed experimentally. Both compounds act in a manner that is not specific to one particular protein and thus are useful against a multitude of amyloidogenic proteins, yet they act via distinct putative mechanisms. CLR01 disrupts protein aggregation through specific binding to lysine residues, whereas the mechanisms underlying the activity of EGCG are only recently beginning to unveil. We discuss current in vitro and, where available, in vivo literature related to EGCG and CLR01's effects on amyloid β-protein, α-synuclein, transthyretin, islet amyloid polypeptide, and calcitonin. We also describe the toxicity, pharmacokinetics, and mechanism of action of each compound.
reducing the steady-state concentration of the toxic oligomers [7] [8] [9] . However, the therapeutic applicability of this approach is questionable because amyloid deposits may be toxic themselves, the very process of their growth may contribute to cytotoxicity and tissue damage [10] , and accelerating fibril formation may induce a harmful pro-inflammatory response [11] .
An ideal assembly inhibitor would interact with different conformations of the offending protein, which would enable the inhibitor both to block formation of toxic oligomers and to dissociate already-formed aggregates into nontoxic forms. Importantly, these forms should be soluble and amenable to degradation by the natural clearance mechanisms; otherwise, even if they are benign, they may accumulate and disrupt cellular function by sheer mass action. Examples of such inhibitors include predominantly two types of compoundspeptides derived from the amyloid proteins themselves [12, 13] , or found through screening in vitro or in silico [14] [15] [16] , and small molecules found empirically [17, 18] .
Though small-molecule drug candidates typically possess superior pharmacological characteristics relative to peptides, for example higher biological stability and bioavailability, a rational basis for prediction of small-molecule efficacy is difficult to define and studies often are based on screening of large libraries or empirical findings. A particular difficulty in the amyloid field is the lack of specific and stable structures of the targets [19] that would allow efficient screening of potential pharmacophores in silico or in vitro. The absence of well-defined structures is partially the cause of the current reality in which neither the protein self-assembly process nor the interaction of the target proteins with inhibitors or cells is sufficiently understood [20] . Due to these obstacles, most efforts geared at discovering and testing new protein oligomerization inhibitors/modulators for different amyloid-related diseases have relied on empirical observations [21] . A particularly prominent trend has been the use of nutraceuticals -compounds isolated from natural food sources, for which empirical or epidemiological data suggested therapeutic potential [22] . The advantage here is cleareven if we do not know how or why these compounds work, at least we can reasonably expect them to be safe for human use [23] .
If the main criterion for selection of aggregation modulator molecules is known safety based on many years of use, one might expect that the compounds available would have diverse structures. Surprisingly, however, the majority of the compounds reported in the literature based on this strategy are polyphenols or flavonoids [24, 25] . The mode of action of these compounds, i.e., how they interact with amyloidogenic proteins or why the polyphenolic/flavonoid structures confer affinity for amyloid sequences, is unclear. Nevertheless, it has become evident that the binding of these compounds to the red-wine component resveratrol [27] , or the coffee-bean extracted caffeic acid [28, 29] can modulate the self-assembly process and inhibit the toxicity of multiple proteins [9] . Many of these compounds have additional activities, including anti-oxidant, anti-inflammatory, or chelatory actions that often are considered beneficial for treatment of amyloid-related Translational Neuroscience effects in various disease models, establishing it as a broad-spectrum drug candidate. Based on screening a library of ~5,000 natural substances for inhibitors of aggregation of mutant huntingtin (Htt) exon 1 containing a polyglutamine expansion, EGCG was identified as the only purified compound (as opposed to plant extracts) with substantial inhibitory activity [43] . Epidemiologic studies of PD and cognitive impairment [44] [45] [46] showed a moderate risk reduction in habitual tea drinkers compared to non-drinkers, supporting a role for EGCG as a protective compound in PD, though the protective activity could not be ascribed directly to inhibition of protein aggregation, because of EGCG's other various reported beneficial therapeutic effects [47] [48] [49] [50] [51] [52] [53] [54] [55] .
Further investigation of the anti-aggregation activity showed that EGCG modulated or inhibited amyloid assembly of a number of amyloidogenic polypeptides, including amyloid β-protein (Aβ, related to AD), α-synuclein (related to PD), islet amyloid polypeptide (IAPP, also known as amylin, related to type-2 diabetes), Htt (related to Huntington's disease), the human immunodeficiency virus enhancer factor -semen-derived enhancer of virus infection (SEVI), and the Plasmodium falciparum merozoite surface protein 2 (related to malaria) [43, [56] [57] [58] [59] [60] [61] [62] [63] . EGCG also causes conversion of the In amyloid fibrils, the major forces holding together the cross-β structure are hydrogen bonds and hydrophobic interactions. In contrast, in the early stages of the aberrant self-assembly of amyloidogenic proteins, when oligomers and nuclei form, the contribution of hydrogen bonding and β-sheet structure is lower. In these early steps, the self-assembly is mediated by a combination of hydrophobic and electrostatic interactions.
As Lys is the only proteinogenic amino acid that effectively forms both hydrophobic and electrostatic interactions in peptides and proteins and contributes substantially to these early self-assembly processes, the ability of MTs to bind specifically to the amino acid Lys was hypothesized to interfere with both these types of interactions within and among polypeptides [9, 65 ]. This hypothesis was tested and concluded to be true by our group and our many collaborators over the last several years.
Lys is a ubiquitous residue and therefore the strategy held promise to produce broadspectrum inhibitors. At the same time, binding of MTs to exposed Lys residues in virtually any protein raised obvious concerns about potential toxicity. However, this was found not Lys residues with micromolar affinity, which is relatively weak but has been found to be sufficient for modulating the assembly and inhibit the toxicity of multiple amyloidogenic proteins without causing toxicity in cell culture unless substantially higher concentrations were used [69] . These data are consistent with in vitro enzyme inhibition studies, which required MT concentrations at least an order of magnitude higher than those needed for inhibition of amyloidogenic proteins [68, 70] and with data showing beneficial effects with no associated toxicity in animal models [71, 72] .
Below we compare and contrast in detail the in vitro and in vivo activities, modes of action, and drug-like characteristics of the broad-spectrum inhibitors EGCG and CLR01.
E ects on Aβ toxicity and assembly in vitro and in cell culture [58] . These cells previously had been shown to secrete highly neurotoxic dimers and trimers into the culture medium [79, 80] , though the toxic effect actually may require formation of protofibrils [81] . Pre-formed intracellular Aβ42 aggregates in these cells were found by immunofluorescence microscopy to disappear after three days of EGCG treatment [58] .
This finding and the cytoprotective effects of EGCG treatment against Aβ42 oligomers generated in tissue-culture medium [58] , led to the hypothesis that EGCG-mediated remodeling of amyloid assemblies likely protects cells from Aβ42-induced toxicity [58] .
Various concentrations of EGCG incubated with 15 μM soluble Aβ42 caused prolongation of the fibrillization lag phase, even when 10-fold molar excess Aβ42 to EGCG were mixed together [57] . A 72-h incubation of Aβ42 with EGCG caused formation of mostly spherical or amorphous structures, in contrast to typical Aβ42 protofibrils and fibrils, which were the predominant morphology without EGCG treatment. These findings suggested that EGCG bound to Aβ oligomers and prevented their conversion into fibrils [58] .
To examine the effect of EGCG on Aβ oligomerization, 50 μM Aβ42 were incubated in the absence or presence of EGCG and probed using the oligomer-specific antibody A11 [82] by dot-blotting [57] . A11 recognized untreated Aβ42 following incubation for 6-24
h, but not Aβ42 incubated with EGCG, whereas 6E10 (a monoclonal antibody against Aβ and APP) reacted with both treated and untreated Aβ42 [57] . The authors concluded that EGCGstabilized Aβ42 oligomers, which likely differed structurally from the A11-reactive amyloid oligomers described previously. In agreement with previous studies [57, 58] , Aβ oligomers produced in the presence of EGCG did not seed Aβ fibril formation, suggesting that in the presence of EGCG, Aβ oligomers adopt distinct structures than those formed in the absence of EGCG, and these structures cannot transform into protofibrils or fibrils [84] .
Solid-state NMR experiments showed that Aβ40 assemblies adopted a well-defined structure, in which residues 22-39 formed β-sheets, whereas the N-terminus (residues 1-20) was unstructured. The characteristic Asp23-Lys28 turn, which previously had been identified as a key structural feature in Aβ fibrils [89, 90] , monomers [91] , and oligomers [92] , was present in these Aβ assemblies [84] . Overall, the NMR data suggested a model in which EGCG binds to unfolded Aβ40 by aromatic interactions.
According to the model, during aggregation, Aβ40 folds into a hairpin structure, in which the C-terminus adopts a β-sheet conformation whereas residues 10-20 cannot do so due to steric interference by EGCG [84] . [69] . In contrast to the fast dissociation of fibrils by EGCG, which was accomplished within hours [58] , dissociation by CLR01 was substantially slower and required several weeks for completion [69] . A potential explanation for the major difference in reaction rate is covalent modification of Aβ by EGCG These observations suggested that EGCG binds to Aβ oligomers but not monomers, in agreement with the study by Palhano et al. [78] .
E ects on tau toxicity and assembly in vitro
Tau is a microtubule-associated protein that is most abundantly found in neurons.
Hyperphosphorylation of tau occurs in AD
and several other neurodegenerative diseases The EGCG-treated mice also showed ~50% reduction in both total brain Aβ levels and in deposited Aβ burden [112, 113] . Mice treated with EGCG through either administration route also showed improved performance in the radial arm water maze [113] , a task of working memory. In a different study, one week of oral 3 mg/kg EGCG treatment of mice expressing a presenilin 2 mutation (Asn141→Ile) [114] showed decreased levels of Aβ42, measured by ELISA, compared to vehicle-treated mice [115] .
Intracerebroventricular injections of Aβ42
in mice resulted in memory dysfunction, as measured by passive avoidance and Morris water maze tests, neuronal apoptosis, an increase in β-and γ-secretase activities, and a decrease in α-secretase activity [115] . In addition, an increase in the activation of extracellularsignal-regulated kinase, the mitogen-activated protein kinase system, and the nuclear factor κ-light-chain-enhancer of activated B cells protein complex was observed in these mice.
These systems have been implicated in Aβ-
induced neuronal cell death in vitro [116] . Mice pre-treated orally for three weeks with 1.5 mg/ kg or 3 mg/kg EGCG showed dose-dependent improvement of all these pathological effects [115] . A rat model in which Aβ40 was injected directly into the hippocampus also showed improved psychomotor coordination and working memory when the animals were pretreated with daily IP injections of 10 mg/kg EGCG for three weeks [117] .
Three weeks of oral EGCG pre-treatment of a mouse model utilizing intracerebroventricular [118] or IP [119] administration of lipopolysaccharide, a pro-inflammatory agent, to induce Aβ deposition by increasing levels of APP and activities of β-and γ-secretases [118] [119] [120] , showed a dose-dependent decrease in APP and Aβ levels and the activities of the secretases [118, 119] . An improvement in memory impairment measured by the passive avoidance [118] and Morris water maze tests also was observed [118, 119] In addition to the Aβ-related effects of EGCG, the polyphenol also has mitochondrial restorative properties [47] . Mitochondria from the APP swe /PS1ΔE9 [127] double-transgenic mouse model of AD treated orally with ~37 mg/kg/day EGCG revealed a rescuing effect of EGCG on mitochondrial respiratory rates, mitochondrial membrane potential, reactive oxygen species production, and ATP levels by at least 50% in the hippocampus, cortex, and striatum. Hippocampal mitochondrial Aβ levels and total brain insoluble Aβ levels were also decreased by 50% and 13%, respectively, following EGCG treatment [47] . Whether the restorative mitochondrial effects of EGCG treatment were direct or indirect is yet to be determined.
CLR01:
The effect of CLR01 on AD-related brain pathology was determined in a tripletransgenic mouse model of AD [128] . E ects on α-synuclein toxicity and assembly in vitro Immunofluorescence microscopy showed that α-synuclein aggregates remained uniformly red or green after addition of equimolar EGCG (50 μM), indicating that EGCG mediated direct fibril restructuring and did not cause release of monomers or small oligomeric assemblies that would subsequently reassemble into larger protein aggregates [58] . Altogether, these findings suggested that EGCG bound directly to pre-formed α-synuclein fibrils and transformed them into smaller, non-fibrillar structures.
To test whether α-synuclein assemblies generated by EGCG addition might promote fibril formation, in vitro seeding experiments using pre-formed α-synuclein fibril fragments and EGCG-stabilized assemblies were performed [57] . When equal amounts of either EGCG-stabilized α-synuclein assemblies or α-synuclein fibrils were added to an excess of unpolymerized α-synuclein, fibrillization was efficiently seeded by sonicated fibrils, whereas EGCG-stabilized α-synuclein oligomers had no effect [57] . Ehrnhoefer et al. also characterized EGCG-stabilized α-synuclein assemblies for A11
immunoreactivity. Using time-resolved dot blotting, formation of A11-reactive amyloid assemblies was suppressed efficiently by addition of EGCG, similar to findings described for Aβ in the same study [57] .
The effect of CLR01 on α-synuclein aggregation was investigated using ThT fluorescence, EM, and native PAGE [72] .
ThT uorescence measurements showed that CLR01 inhibited formation of β-sheet completely at α-synuclein:CLR01 concentration ratio 1:1, respectively, and partially at 10:1 ratio.
In disaggregation experiments, α-synuclein was allowed to aggregate for 60 days and tyrosine hydroxylase activity and dopamine levels in the striatum [139] . In a separate study, in which EGCG was administered at 10 or 50 mg/kg/day, dopaminergic cell death rate was reduced to less than 50% of control and no toxicity was observed in either group [140] .
MPTP-treated mice showed a 20% increase in levels of nitric oxide synthase, which causes toxicity by increasing nitric oxide [140] .
Treatment with EGCG or oral tea administration not only reduced levels of neuronal nitric oxide synthase [139] , but also lowered them down to control levels [140] . MPTP-administered mice treated with a combination of EGCG and rasagiline, a monoamine oxidase B inhibitor, showed a synergistic neuroprotective effect in the substantia nigra at doses below the therapeutic level of each compound [141] . A suggested mechanism for this response was a potential convergence of the individual effects of the compounds to increase levels of the Ser/Thr kinase Akt/protein kinase B [141] . A cDNA microarray analysis of the early and late genes involved in the MPTP model suggested a domino effect resulting from the early gene changes that led to cell death in the substantia nigra [142] . EGCG treatment reversed some of the gene expression changes and reduced cell death, supporting the role of those changes in neurodegeneration [142] .
Rats pre-treated orally for 14 days with up to 2 mg/kg of EGCG followed by lesion surgery with 6-hydroxydopamine -a synthetic neurotoxin that selectively destroys dopaminergic and noradrenergic cellsshowed subtle improvement in postural abnormalities and ability to cross a narrow beam [143] . However, this study did not demonstrate a rescue in dopaminergic cell loss [143] . In addition to the neuroprotective and striatum [144] . The EGCG treatment also exerted a strong neuroprotective effect against kainic-acid-induced oxidative neuronal death in the rat hippocampus [144] .
CLR01: CLR01's in vivo effects on α-synuclein aggregation and toxicity were first tested in a zebra fish (Brachydanio rerio) model, which expresses human wild-type α-synuclein under a neuronal promoter that causes a deformed body phenotype due to neuronal apoptosis, and early death [72] . Addition of CLR01 to the water environment of the fish at 1 or 10 μM caused dramatic, dose-dependent improvements in both the body phenotype and the survival of the fish [72] . Immunohistochemical analysis of the zebra fish neurons showed abundant aggregated α-synuclein in untreated fish, whereas only soluble α-synuclein was observed in fish treated with CLR01. Western blot analysis in the absence or presence of the 26S ubiquitin-proteasome system (UPS) inhibitor, lactacystin, showed that by blocking α-synuclein aggregation, CLR01 prevented the known inhibition of the UPS by α-synuclein oligomers [145, 146] , leading to increased clearance of α-synuclein [72] . This latter finding provided important support for the "processspecific" mechanism of action of CLR01 by demonstrating that the labile binding of CLR01 to Lys residues in α-synuclein was sufficient for inhibition of aggregation, yet at the same time did not interfere with ubiquitination, which is required for UPS degradation [72] .
A new zebra fish study [147] used the fungicide ziram (zinc bis(dithiocarbamate)), an inhibitor of ubiquitin E1 ligase of the UPS [148] [149] [150] , which is linked to increased risk of PD [151] . Inhibition of E1 ligase has been shown to damage dopaminergic neurons preferentially and to increase α-synuclein levels and synaptic currents [150, 152] . Exposure of zebra fish embryos to 10-1,000 nM ziram led to dose-dependent altered swimming, selective dopamine cell loss, and early death.
UPS inhibition was measured using a degron-green fluorescent protein system [72] and 
E ects on TTR aggregation and toxicity in vitro

EGCG: EGCG interaction with TTR was
assessed by binding assays using control plasma 6, TTR alone was mainly fibrillar whereas the EGCG-containing preparations did not change [155] . Similarly, EGCG was found to inhibit TTR aggregation in media of a rat Schwannoma cell line, which secretes TTR Leu55→Pro, as determined by a filter-binding assay [155] .
Because structural [156] and electrophoretic evidence [155] showed that EGCG-TTR interaction sites are distinct from the thyroxin- CLR01 inhibited this toxic effect with IC 50 = 54 ± 19 μM, suggesting that inhibition of toxicity occurred through a different mechanism from inhibition of fibrillogenesis [69] . Deciphering these mechanistic differences will require further studies.
E ects on TTR toxicity in vivo
EGCG: A single-center observational study conducted in patients with familial amyloidotic TTR cardiomyopathy with an intake of 500-700 mg EGCG per day for 12 months, reported either no increase or a decrease in the left ventricular myocardial mass [157] . Left ventricular function is positively correlated with better prognosis in cardiac amyloidosis [158] . Though this study was very preliminary, without a control cohort, and the increase in left ventricular mass varied Translational Neuroscience [159] , the authors also found an increase in the mean mitral annular systolic velocity, a restorative effect, and a decrease in the total and low-density lipoprotein-associated cholesterol levels with no serious adverse events, suggesting that treatment with EGCG might be beneficial in these patients [157] .
Six weeks of 100-mg/kg/day oral treatment with EGCG was examined in a mouse model of FAP [160] . These mice express human TTR Val30→Met on a TTR-null background and are heterozygous for heat-shock transcription factor 1 [161] . Mice were treated at a pre-amyloid deposition age resulting in a decrease of TTR deposition by ~50%, compared to untreated control mice, along the gastrointestinal tract and the peripheral nervous system [160] .
Disease-associated biomarkers of endoplasmic reticulum stress, protein oxidation, and apoptosis also were reduced. Treatment of older mice at a post-amyloid deposition stage produced a decrease in amyloid deposits and the associated biomarkers [160] . investigated the fibril-seeding ability of EGCGtreated IAPP assemblies and found that they did not seed IAPP fibril formation [56] . EGCG also disaggregated and converted IAPP fibrils to smaller aggregates with a lower tendency to self-assemble [56] .
In cytotoxicity experiments, the effects of equimolar EGCG and IAPP (30 μM each)
mixtures on rat INS-1 cells were compared [56] . 
E ects on calcitonin aggregation and toxicity in vitro
Calcitonin is a 32-residue polypeptide hormone secreted from the thyroid gland in response to high serum [Ca 2+ ] to exert hypocalcemic effects and reduce bone resorption by osteoclasts 
Toxicity
EGCG: Green tea has a long history as one of the world's most popular beverages and is recognized widely as beneficial for health.
However, as extracts and dietary supplements of green tea and purified EGCG have become more popular, some case studies and some formal studies of their toxicity have shown that at high levels they often lead to hepatotoxicity [187] .
Cell assays in bacteria and mouse lymphoma L5178Y tk +/-have shown that up to 450 μM EGCG were not genotoxic [188] . In animal experiments, a daily dose of up to ~1,000 mg/kg EGCG did not show teratogenicity in rats [189] . A topical dose of 1,860 mg/kg of EGCG resulted in minor dermal irritation in rats and guinea pigs but not in rabbits [190] .
Administration of 100 mg EGCG to rabbit eye resulted in moderate-to-severe irritation and slight-to-moderate corneal opacity [190] . A single dose of 2,000 mg/kg was >80% lethal in rats [190] and single doses of 1,500 mg/ kg or 1,200 mg/kg were 85% or 40% lethal in mice, respectively [191] . Two days of oral 750 mg/kg/day or 7 days of intraperitoneal 50 mg/kg/day were 50% and 67% toxic in mice, respectively [191, 192] , whereas 13 weeks of oral 500 mg/kg/day showed no toxicity in rats [190] . Toxicity in mice often was observed in the form of increased alanine-aminotransferase levels suggesting hepatotoxicity [192] , and/ or by oxidative stress [191] . Plasma EGCG concentrations in mice tend to be closer to levels reported in human studies compared to levels in rats, in which administration of similar doses results in higher plasma concentrations [188] . Chronic toxicity studies in beagle dogs, showed 67% lethality within 26 weeks of daily doses of 200-800 mg/kg Polyphenon E, a pure and standardized green tea extract, when the dogs fasted for 20 h prior to EGCG administration [193] . However, replication of the 200-mg/kg dose for 13 weeks did not result in any deaths compared to the previous study, in which 3/8 deaths were recorded at that dose [193] . Fasting dogs receiving a single dose of 120 mg/kg/day or 400 mg/kg/day died or were sacrificed due to their moribund condition starting at 7 weeks of a 13-week study [190] .
Prior to death, dogs presented with occasional vomiting, frequent diarrhea, weight loss, and anorexia [190] . Autopsy of dogs from the 120-mg/kg and 400-mg/kg groups consistently showed thymus lymphoid atrophy and some kidney necrosis, liver necrosis, erosion of the stomach, and limited cases of hemolytic anemia and myocardial necrosis [190] . In contrast, no adverse events were observed when non-fasting dogs were treated with 400 mg/kg in two doses [190] .
The cytochrome P450 (CYP) superfamily of enzymes is involved in phase-1 metabolism and accounts for ~75% of metabolic reactions in the body. Thus, inhibition or activation of these enzymes may cause metabolic toxicity or drug-drug interactions [194] . EGCG showed inhibition of CYP19 (aromatase enzyme for estrogen biosynthesis) and activation of CYP3A subfamily enzymes and CYP2E1 when administered by intraperitoneal injection at 25 mg/kg/day for 7 days to female mice [192] .
In vitro, 250 μM EGCG inhibited CYP2B1 [195] .
Acute human studies showed that single doses of 1,200 mg or 1,600 mg EGCG were safe and well tolerated, though nausea was reported [196, 197] . Doses of 800 mg/day for 10 days also were safe and well tolerated, though an excretion saturation limit was reached [198] .
Doses of ~800 mg/day for 4 weeks or 4 months in 1-3 doses per day showed mild adverse events, in the form of upset or achy stomach, constipation, nausea, headache and dizziness, and muscle pain. Abdominal discomfort and mild constipation also was recorded in the placebo group [199, 200] . A case study reported a man drinking 6 cups of green tea (600-1200 mg EGCG) per day for 4 months who presented with jaundice and increased plasma alanine aminotransferase [201] . A 6-month chronic study of 800-1,600 mg/day administered in two doses determined the maximum tolerated dose, defined as the dose that causes 25% dose-limiting toxicity, to be 1,200 mg per day, with liver function abnormalities observed at the highest dose [202] . In addition, at least 25 reports have been made of hepatotoxicity following use of herbal supplements containing 10-29 mg/kg/day green tea extracts ( Table 1 in Mazzanti et al. 2009) [203, 204] . In the 30-day study, no signs of discomfort were observed in either group [205] .
Serum chemical analysis of mice from both studies showed no differences in the low-dose groups compared to controls. In contrast, mice in the single 100-mg/kg dose group showed signs of acute hepatotoxicity [205] . Histological findings in the heart, lung, kidney, and brain of all the treated mice were indistinguishable from vehicle-treated mice, whereas liver injury was observed in the 100-mg/kg dose group [205] .
In vitro studies of CLR01 inhibition of five major CYP enzymes showed IC 50 values of 1.5 μM for 2C19, 1.7 μM for 3A4, 2.2 μM for 2C9, 3.6 μM for 2D6, and >20 μM for 1A2 [71] . Inhibitory potencies are thought to have an increased risk for drug-drug interaction complications if the IC 50 is <1 μM [206] , which was not found for CLR01 with any of the 5 isoforms studied.
In vitro studies of CLR01 activation of the CYP system found minimal activation up to 50 μM [71] . [207] [208] [209] .
Oral bioavailability of EGCG can be increased by administration to fasting people [197] , albeit, with an increased risk of toxicity as suggested by the dog studies discussed above.
Catechins appear in plasma after ~30 min and reach maximum levels between 1-3 h postingestion in a monophasic manner suggesting that the key site of absorption is the small intestine [207, 208, 210] . EGCG is found at very low levels, if at all, in urine [207, 211, 212] and interconversion or de-gallation from EGCG to EGC is very limited [211] .
Conflicting results have been published regarding whether EGCG is mainly in an unconjugated or conjugated, i.e., sulfated or glucuronidated, form in plasma. Thus, one study reported 92% unconjugated EGCG [194] , whereas another found 72% of EGCG to be conjugated, mostly in a sulfated form [212] .
Methylated catechins, most likely by COMT [213] also have been detected in the plasma [214] . Interestingly, as mentioned above, EGCG is a COMT inhibitor [144] . The beneficial or detrimental significance of EGCG methylation has been debated. Methyl capping of other avones has been shown to increase metabolic stability, and by preventing glucoronidation and sulfation, to improve bioavailability [215] .
In addition, an increased anti-allergic effect has been reported for methylated EGCG and other catechins relative to the unmethylated forms [216] . On the other hand, other studies have reported a decrease in the antioxidant activity of methylated catechins [217] . one hour showed 100% stability [71] . The initial plasma concentration measured following an intravenous injection of 1 mg/kg CLR01 to mice was 10-11 μM and the half-life was ~2.5 h in mice [205] . In blood-brain-barrier studies, one hour following intravenous injection, brain levels of 3 H-CLR01, measured by scintillation counting, were ~2% of the levels found in the blood [71] . Importantly, the binding of CLR01 is highly labile and the affinity of the compound for Lys is in the micromolar range [68, 69] , although higher affinity may be achieved in certain cases, depending on the number of Lys residues in the target protein and the specific sequence of the protein [134] . The high lability and moderate affinity prevent Translational Neuroscience CLR01 binding to structured proteins from interfering with normal physiological function.
Mechanisms of action
Thus, despite its ability to bind exposed Lys residues on virtually any protein, as discussed above, the compound was found to have weak iatrogenic toxicity in cell culture and animal models. Direct demonstration of the specificity of CLR01's mechanism for modulation of aberrant assembly of amyloid proteins was provided by examining its effect on a regulated physiologic assembly process -that of tubulin polymerization. The CLR01 concentration required for modulation of tubulin polymerization was ~50-times higher than that needed for inhibition of amyloidogenic proteins [205] . 
Conclusion
